Therapeutic Intermittent Fasting and Cancer: Current Research Evidence
Intermittent fasting is a dietary approach that alternates periods of eating with periods of fasting. Recent research suggests this practice may have benefits for cancer prevention and treatment. This article examines the current scientific evidence.
What is Intermittent Fasting?
Intermittent fasting refers to eating patterns that cycle between periods of eating and fasting. There are several common types:
Time-restricted eating: Eating is limited to a specific window each day. A common pattern is eating within an 8-hour window and fasting for 16 hours.
Alternate-day fasting: Calorie intake is restricted every other day.
5:2 fasting: Normal eating occurs 5 days per week. Calorie intake is significantly reduced on 2 non-consecutive days.
Fasting-mimicking diet: A low-calorie, plant-based diet is followed for several consecutive days per month. This mimics the metabolic effects of fasting while providing some nutrition.
How Fasting May Affect Cancer Cells
Research shows that fasting creates metabolic changes in the body. These changes may affect cancer cells differently than normal cells.
Metabolic switching
During fasting, the body switches from using glucose as its primary fuel to using ketones from fat breakdown. Cancer cells rely heavily on glucose for energy. Normal cells can adapt to use ketones as fuel, but cancer cells have limited ability to make this metabolic switch.
Reduced growth factors
Fasting reduces levels of insulin-like growth factor 1 (IGF-1), a hormone associated with increased cancer risk. Lower IGF-1 levels may slow cancer cell growth.
Autophagy activation
Autophagy is a cellular process that breaks down and recycles damaged cellular components. Intermittent fasting activates autophagy through nutrient-sensing pathways that respond to reduced energy availability. This process helps eliminate damaged proteins and organelles from cells.
Protection of normal cells
During fasting, normal cells enter a protective state with reduced metabolic activity. This makes them more resistant to stress. Cancer cells cannot enter this protective state because of their altered metabolism.
Immune system enhancement
Recent research in mice shows that fasting can reprogram natural killer cells, a type of immune cell. These cells become better able to survive in tumor environments and fight cancer more effectively.
Clinical Research Findings
Current evidence in humans
A 2024 review examined clinical studies of intermittent fasting in cancer patients. The review found that some studies suggest intermittent fasting may improve fatigue and reduce gastrointestinal side effects in certain patients undergoing cancer treatment.
Emerging evidence also shows that intermittent fasting may reduce DNA damage in normal cells and promote favorable changes in immune cell function.
Research in mice showed that 5:2 intermittent fasting reduced development of liver cancer in animals with pre-existing liver inflammation. The fasting regimen also protected against fatty liver disease and chronic liver inflammation.
Limitations of current research
Most clinical studies have been small and short-term. Larger controlled studies are necessary to determine the effectiveness of intermittent fasting as a supportive intervention during cancer care.
Twenty-one clinical trials have been conducted or are ongoing on fasting in cancer. These studies use various fasting regimens across different tumor types.
Potential Benefits
Research suggests several potential benefits of intermittent fasting for cancer patients:
Reduced treatment side effects: One small study showed intermittent fasting may reduce chemotherapy side effects such as fatigue, nausea, and mouth sores.
Enhanced treatment effectiveness: Preclinical studies suggest fasting may increase cancer cell sensitivity to chemotherapy and radiotherapy while protecting normal cells from harmful effects.
Metabolic improvements: Intermittent fasting may lower blood glucose levels and reduce body fat ratio. This may benefit patients at risk of high blood sugar and weight-related side effects from cancer treatments.
Inflammation reduction: Studies show intermittent fasting reduces inflammatory markers such as C-reactive protein and tumor necrosis factor alpha.
Important Safety Considerations
Intermittent fasting is not appropriate for all cancer patients. Several important safety factors must be considered:
Risk of malnutrition
A major concern is that fasting might cause malnutrition, muscle loss, and cachexia in vulnerable patients. However, clinical studies published so far have not documented cases of severe weight loss or malnutrition with noticeable effects.
Increased nutritional needs
Cancer patients need more protein and calories than average to support healing, fight infections, and maintain weight. Insufficient intake can impair recovery and cause frailty.
Individual variation
The effects of intermittent fasting on cancer vary depending on cancer type and stage. Some patients may benefit while others may not notice effects.
Who should avoid fasting
Very few cancer patients are appropriate candidates for intermittent fasting. It is generally only considered for patients who feel well, have not lost weight, and want to try it.
Medical Supervision Required
Always consult healthcare providers: Any cancer patient considering intermittent fasting must first discuss it with their oncologist and healthcare team.
Close monitoring needed: Nutritional status, weight, and overall health must be monitored regularly during fasting protocols.
Individualized approach: Fasting protocols must be tailored to individual patient needs, cancer type, treatment stage, and overall health status.
Current Research Directions
The National Cancer Institute has funded multiple studies examining how intermittent fasting affects cancer incidence, treatment response, and outcomes.
Future research should evaluate intermittent fasting in the context of combined diet, exercise, and nutrition strategies. Studies should also examine effects on the circadian system and gut microbiome.
Researchers are working to develop drugs that mimic the metabolic effects of fasting. These could benefit patients who cannot or do not want to fast.
Intermittent fasting shows promise as a supportive approach in cancer care. Research suggests it may enhance treatment effectiveness and reduce side effects through several mechanisms. These include metabolic switching, autophagy activation, growth factor reduction, and immune system enhancement.
However, current evidence is preliminary. Most studies have been conducted in animals or in small human trials. Larger, long-term clinical studies are needed.
Intermittent fasting is not appropriate for all cancer patients. It carries risks of malnutrition and muscle loss in vulnerable individuals. Cancer patients require increased nutrition to support healing and maintain strength.
Any cancer patient considering intermittent fasting must work closely with their healthcare team. Medical supervision is essential to ensure safety and appropriate nutritional support.
References
- Li Sucholeiki R, Propst CL, Hong DS, George GC. Intermittent fasting and its impact on toxicities, symptoms and quality of life in patients on active cancer treatment. Cancer Treatment Reviews. 2024;126:102725.
- Effect of fasting on cancer: A narrative review of scientific evidence. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC9530862/
- de Groot S, Lugtenberg RT, Cohen D, et al. Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial. Nature Communications. 2020;11:3083.
- Intermittent Fasting in Cancer: a Role in Survivorship? PubMed. 2022. PMID: 35639262.
- Delconte RB, et al. Fasting primes natural killer cells to better fight cancer. Immunity. 2024. Memorial Sloan Kettering Cancer Center.
- Gallage S, et al. Intermittent fasting protects against liver inflammation and liver cancer. Cell Metabolism. 2024. German Cancer Research Center.
- Wolska W, et al. The Role of Intermittent Fasting in the Activation of Autophagy Processes in the Context of Cancer Diseases. International Journal of Molecular Sciences. 2025;26(10):4742.
- Time-restricted eating and cancer: lessons learned and considerations for a path forward. PMC. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC12229459/
- Freedland S. Researchers Look to Fasting as a Next Step in Cancer Treatment. Cedars-Sinai. 2024.
- Lepkowski H. What To Know About Intermittent Fasting When You Have Cancer. Henry Ford Health. 2024.
Disclaimer – Limited Responsibility:
The information provided on this website is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your doctor, a qualified healthcare professional, or a certified herbalist regarding any health-related concerns or questions. Do not disregard professional medical advice or delay seeking medical attention based on something you have read on this website.
The use of herbal remedies should be approached with care and in consultation with a healthcare professional. Individual results may vary, and herbal treatments may not be suitable for everyone. Always confirm the safety and suitability of any herbal remedy with a healthcare provider before use.
You are solely responsible for verifying the accuracy of the information provided on this website. We accept no responsibility for the information contained herein. It is possible that we have written something incorrect without knowing, and you should always use your own judgment.
Herb Woman has both a Facebook page and a Facebook group that you can use to stay up to date. You are welcome to reach out through the Facebook group and ask for advice of all kinds related to plants and health, directly from herbalist María Hrefna.
Link to the Herb Woman Facebook page:
https://www.facebook.com/herb.woman.europe
Link to the Herb Woman Facebook group:
https://www.facebook.com/groups/herbwoman
All advice is free of charge.
